NLS Global report

The pharma giant was recently granted a patent on their vaccine for pneumonia in India, which has been highly questioned by for example Medecins sans Frontiers (MSF). The patent approval means that other pharma companies are not allowed to manufacture cheaper versions of the vaccine and this is a major backlash in the fight for […]

The European Commission (EC) opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines. The formal investigation address concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. “When we get sick, […]

Novartis has received a FDA approval for its CAR-T treatment tisagenlecleucel, a first-ever cell therapy for a rare form of acute lymphoblastic leukemia. The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up […]

The CEO of global pharma giant Merck, Kenneth Frazier, is resigning from President Donald Trump’s manufacturing council. The resignation came after a weekend of violence at a white-nationalist and neo-Nazi protest in Charlottesville, Virginia. The president did not explicitly condemn white supremacists. In a statement Frazier said: “America’s leaders must honor our fundamental values by […]

The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s withdrawal from the European Union and the Agency’s relocation. “Preparing for the move, managing the necessary changes, and addressing challenges such as possible losses in skilled and experienced staff, […]

Proposed drastic cuts to U.S. science agencies and departments by President Donald Trump have life science researchers on edge about the fate of current and future projects, not to mention the nation’s standing in the scientific community.